<SEC-DOCUMENT>0001013762-25-002955.txt : 20250327
<SEC-HEADER>0001013762-25-002955.hdr.sgml : 20250327
<ACCEPTANCE-DATETIME>20250327061325
ACCESSION NUMBER:		0001013762-25-002955
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250327
FILED AS OF DATE:		20250327
DATE AS OF CHANGE:		20250327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		25775068

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0235874-6k_alterity.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>





     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
6-K</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF FOREIGN PRIVATE ISSUER</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO RULE 13a-16 OR 15d-163</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the month of March 2025</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alterity
Therapeutics Limited</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Office)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm">333-251073</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm">333-248980</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm">333-228671</a>) and our
Registration Statements on Form F-3 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm">333-274816</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm">333-251647</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm">333-231417</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm">333-250076</a>)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALTERITY
THERAPEUTICS LIMITED</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a
development stage enterprise)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are submitted:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font-style: normal; vertical-align: top; text-align: justify; background-color: rgb(204,238,255); font-weight: normal">
    <TD STYLE="font-style: normal; width: 9%; text-align: left; font-weight: normal">99.1</TD>
    <TD STYLE="font-style: normal; width: 1%; font-weight: normal"><B>&nbsp;</B></TD>
    <TD STYLE="font-style: normal; text-align: justify; width: 90%; font-weight: normal"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="ea023587401ex99-1_alterity.htm">Alterity Completes Last Patient Visit in Open-Label Trial</A></P>

</TD></TR>
  </TABLE>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>SIGNATURE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Alterity Therapeutics Limited</b></font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 4%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 36%">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">/s/ Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Chairman</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: none; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 27, 2025</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif">&nbsp;</div></div><!-- Field: /Rule-Page -->



</BODY>
</HTML>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea023587401ex99-1_alterity.htm
<DESCRIPTION>ALTERITY COMPLETES LAST PATIENT VISIT IN OPEN-LABEL TRIAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Alterity Therapeutics Completes Last Patient
Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&ndash; ATH434 is a
Disease Modifying Drug Candidate Targeting Parkinsonian Disorders &ndash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&ndash; Topline Data
Expected Mid-Year 2025 &ndash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA
&ndash; 27 March 2025:</B> Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (&ldquo;Alterity&rdquo; or &ldquo;the Company&rdquo;), a biotechnology
company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced&nbsp;that the last patient
in the ATH434-202 Phase 2 trial has completed the&nbsp;study. The ATH434-202 is an open label study designed to evaluate the safety, efficacy
and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Following the positive results from our
randomized, double-blind Phase 2 trial<SUP>1</SUP>, we are pleased to announce that the last participant has now completed all clinical
evaluations in our open-label study of advanced MSA,&rdquo; said, David Stamler, M.D., Chief Executive Officer of Alterity. &ldquo;The
202 study gives us the opportunity to evaluate the effects of ATH434 treatment in a population that faces severe challenges due to the
stage of their illness. The data from this study will help guide our development program given the differences between the 202 study and
the double-blind trial. I greatly appreciate the contributions of the trial participants and thank them for their participation. We look
forward to reporting topline data from this study in mid-year 2025.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ATH434-202 Phase 2 Clinical Trial </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ATH434-202 Phase 2 clinical trial is an open
label study, entitled &ldquo;A Biomarker Study of&nbsp;ATH434&nbsp;in Participants with MSA.&rdquo; The Biomarker trial enrolled 10 individuals
with advanced MSA. ATH434-202 study participants received treatment with ATH434 at the 75 mg dose for 12-months. The study will assess
the effect of ATH434 treatment on neuroimaging and protein biomarkers to evaluate target engagement, in addition to clinical measures,
safety, and pharmacokinetics. The selected biomarkers, including brain volume, iron and aggregating &alpha;-synuclein, are important contributors
to MSA pathology and are appropriate targets to demonstrate drug activity. The primary objective of this study is to evaluate the impact
of 12 months treatment with ATH434 on brain volume in a more advanced patient population than was studied in Alterity&rsquo;s randomized
Phase 2 trial. Additional information on the open label Phase 2 trial can be found at&nbsp;clinicaltrials.gov NCT05864365.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ATH434</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alterity&rsquo;s lead candidate, ATH434, is an
oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically
to reduce &alpha;-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone,
it has excellent potential to treat Parkinson&rsquo;s disease as well as various Parkinsonian disorders such as Multiple System Atrophy
(MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to
efficacious levels in animal models of MSA. ATH434 recently announced positive results from the randomized, double-blind, placebo-controlled
Phase 2 clinical trial in patients with early-stage MSA. A second Phase 2 open-label 2 Biomarker trial in patients with more advanced
MSA is ongoing. ATH434 has been granted Orphan Drug Designation for the treatment of MSA by the U.S. FDA and the European Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Multiple System Atrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Multiple System Atrophy (MSA) is a rare, neurodegenerative
disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function
and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability.
MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that
affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes
to falls. A pathological hallmark of MSA is the accumulation of the protein &alpha;-synuclein within glia, the support cells of the central
nervous system, and neuron loss in multiple brain regions. MSA affects at least 15,000 individuals in the U.S., and while some of the
symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no
cure.<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>Multiple System Atrophy | National Institute of Neurological
Disorders and Stroke (nih.gov)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Alterity Therapeutics Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alterity Therapeutics is a clinical stage biotechnology
company dedicated to creating an alternate future for people living&nbsp;with neurodegenerative diseases. The Company is initially focused
on developing disease modifying therapies in Parkinson&rsquo;s disease and related disorders. Alterity recently reported positive data
for its lead asset, ATH434, in a Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive
Parkinsonian disorder. ATH434 is also being evaluated in a Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug
discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is
based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company&rsquo;s website at
www.alteritytherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sources:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>ATH434-201 Phase 2 trial results release</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>
Authorisation &amp; Additional information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor and Media Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ana Luiza Harrop</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">we-aualteritytherapeutics@we-worldwide.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+61 452 510 255</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remy Bernarda</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">remy.bernarda@iradvisory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (415) 203-6386</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.
The Company has tried to identify such forward-looking statements by use of such words as &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;evidences&rdquo; and &ldquo;estimates,&rdquo; and
other similar expressions, but these words are not the exclusive means of identifying such statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Important factors that could cause actual results
to differ materially from those indicated by such forward-looking statements are described in the sections titled &ldquo;Risk Factors&rdquo;
in the Company&rsquo;s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including,
but not limited to the following: statements relating to the Company&rsquo;s drug development program, including, but not limited to the initiation,
progress and outcomes of clinical trials of the Company&rsquo;s drug development program, including, but not limited to, ATH434, and any other
statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks
and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing
of the Company&rsquo;s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future
sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&rsquo;s drug compounds, including, but
not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company&rsquo;s
intellectual property or trade secrets, the uncertainty of successfully enforcing the Company&rsquo;s patent rights and the uncertainty
of the Company freedom to operate.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Any forward-looking statement made by us in
this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as
a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V -P# 2(  A$! Q$!_\0
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M9@J.$HT(U,7C,+0K4U+%0HPY</.A@KUHX95,)^7_ $=LJXPX6X,S/&<;X_\
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MO)(%\1>"?$:P1S7GAWQ%9PR2"&ZA619K.\B+V.K6$D&HZ?--;3 K])U^*8[
M8W*\9BLNS'"U\#CL%6J8?%X3%4I4<1AZ]*7+.G5IS2E&2=FG[T9QE"I3G4IU
M*=2I^Q8/&87,,+A\=@J]+%83%T:>(PV(HS4Z5:C5BITZD)*UU)/9J,HR4H3C
M"<)P@5_'O_P=L_MPM\._@'\*OV&O!>KF'Q5\>=6M_B7\4X;2X>.>T^%7@;4R
M/"^C7@AFC<0^,?'MJ=1B1E*RQ?#^ZMYOW%X5D_KYU75--T/3-2UK6+ZUTS2-
M'L+S5-5U*^F2VLM/TW3[>2[OKZ\N)66*"UM+6&6XN)I&5(HHW=V"J37^4/\
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M/O)1G&4W)3LY)QBM8JPTN:<VYNT9)**=K62W2_7S/XF_^"R?_!1K]M[]GO\
MX+2_ 7]G;X,_M%>./A_\%/%D?[+K:]\/M&C\/MHNH_\ ":_$&YT;Q3YQO]%O
M+X?VS8(L%T4NU^08B\LC(^C?^#HCP7_P42N?A#KGQ#^"'Q!.@?L)^'_@OH^B
M_M-^#T\4^&]/D\2>)-9^+-MIVDE?#E]I\GB+55D;5O"$4TNDW\4(M[:831+'
M!<F?\F_^"^X8_P#!P?\ LRGD@0?L9 ?^'6O2<#KWY(K^J_\ X.!/#VL^)O\
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M1RC1][V;Y4Y/K&SY'*T8\VD5S))0B[I13GU2LWUUT\^MM?,^9_CK_P &V_\
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M7]K[]F_Q7\;9_A_!X#\2?#OQ[\7OA5XV\*Z7XTTWXA>$+CQM\&=8O-$U^^\
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M2_&C]INZEOM'MM&/AN]^,6IZ;J5QX/M4MKR\&HV6@'3A#;ZM.UO<WPE9Y;2
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EN8X)REMI]G&I13IUZM*_LIN#=[N*BI-.VE[-VT3MJD]K:W#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
